Fidelity Investments
FULC icon

Fidelity Investments’s Fulcrum Therapeutics FULC Stock Holding History

Fidelity Investments’s Portfolio FULC Stock Details FULC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$338K Buy
92,327
+31,286
+51% +$190K ﹤0.01% 3453
2026
Q1 		$468K Buy
61,041
+53,350
+694% +$495K ﹤0.01% 3156
2025
Q4 		$87K Buy
7,691
+341
+5% +$3.47K ﹤0.01% 3830
2025
Q3 		$67.6K Buy
7,350
+383
+5% +$2.77K ﹤0.01% 3837
2025
Q2 		$47.9K Buy
6,967
+2,649
+61% +$14.2K ﹤0.01% 3930
2025
Q1 		$12.4K Sell
4,318
-86,147
-95% -$316K ﹤0.01% 4420
2024
Q4 		$425K Sell
90,465
-1,633,550
-95% -$6.03M ﹤0.01% 2992
2024
Q3 		$6.15M Sell
1,724,015
-3,605,931
-68% -$26.8M ﹤0.01% 2070
2024
Q2 		$33M Sell
5,329,946
-34,719
-0.6% -$263K ﹤0.01% 1478
2024
Q1 		$50.6M Sell
5,364,665
-319,950
-6% -$2.86M ﹤0.01% 1324
2023
Q4 		$38.4M Sell
5,684,615
-290,801
-5% -$1.29M ﹤0.01% 1391
2023
Q3 		$26.5M Buy
5,975,416
+421,676
+8% +$1.84M ﹤0.01% 1477
2023
Q2 		$18.3M Sell
5,553,740
-602,588
-10% -$1.77M ﹤0.01% 1678
2023
Q1 		$17.5M Buy
6,156,328
+922,603
+18% +$8.27M ﹤0.01% 1668
2022
Q4 		$38.1M Sell
5,233,725
-2,571,917
-33% -$16.8M ﹤0.01% 1361
2022
Q3 		$63.1M Buy
7,805,642
+1,678,411
+27% +$12M 0.01% 1150
2022
Q2 		$30M Buy
6,127,231
+30,753
+0.5% +$301K ﹤0.01% 1481
2022
Q1 		$144M Buy
6,096,478
+14,161
+0.2% +$200K 0.01% 915
2021
Q4 		$108M Buy
6,082,317
+37,554
+0.6% +$744K 0.01% 1071
2021
Q3 		$171M Buy
6,044,763
+3,665,282
+154% +$69.5M 0.01% 870
2021
Q2 		$24.9M Sell
2,379,481
-36,250
-2% -$366K ﹤0.01% 1748
2021
Q1 		$28.5M Buy
2,415,731
+665,995
+38% +$8.23M ﹤0.01% 1636
2020
Q4 		$20.5M Sell
1,749,736
-86,500
-5% -$978K ﹤0.01% 1707
2020
Q3 		$14.6M Sell
1,836,236
-14,316
-0.8% -$172K ﹤0.01% 1701
2020
Q2 		$33.8M Buy
1,850,552
+68,101
+4% +$1.07M ﹤0.01% 1323
2020
Q1 		$21.3M Buy
1,782,451
+81,700
+5% +$1.31M ﹤0.01% 1376
2019
Q4 		$27.7M Buy
1,700,751
+207,867
+14% +$1.99M ﹤0.01% 1472
2019
Q3 		$9.44M Buy
+1,492,884
New +$16.5M ﹤0.01% 1854

Other funds holding FULC

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.06B AUM 215.32% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $2.2B AUM 156.35% 1-Year Est. Return
NCM
Nantahala Capital Management New Canaan, Connecticut $3.01B AUM 119.46% 1-Year Est. Return
SCM
Suvretta Capital Management New York $5.47B AUM 131.34% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.91% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Jane Street
Jane Street New York $1.21T AUM 78.12% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Fidelity Investments's FULC Position: Q2 2026 in Review

Fidelity Investments increased its Fulcrum Therapeutics (FULC) stake by 51% in Q2 2026, buying an estimated $190K and bringing the position to 92,327 shares worth $338K. The position accounts for ﹤0.01% of the portfolio, ranked #3453.

Fidelity Investments first reported a position in FULC in Q3 2019 and has held it in 28 quarters since. The position peaked at $171M in Q3 2021. 155 funds tracked by Wall St. Rank hold FULC as of Q2 2026.

  • Fidelity Investments held 92,327 shares of Fulcrum Therapeutics worth $338K as of Q2 2026.
  • Fidelity Investments bought 31,286 Fulcrum Therapeutics shares in Q2 2026, an estimated $190K.
  • Fulcrum Therapeutics made up ﹤0.01% of Fidelity Investments's portfolio in Q2 2026, its #3453 holding.
  • Fidelity Investments first reported a position in Fulcrum Therapeutics in Q3 2019 and has held it in 28 quarters since.
  • Fidelity Investments's Fulcrum Therapeutics position peaked at $171M in Q3 2021.
  • 155 funds tracked by Wall St. Rank held Fulcrum Therapeutics as of Q2 2026.

Based on Fidelity Investments's 13F filing for Q2 2026, filed 13 Aug 2026.